<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03186716</url>
  </required_header>
  <id_info>
    <org_study_id>2017670</org_study_id>
    <nct_id>NCT03186716</nct_id>
  </id_info>
  <brief_title>A Trial of Enteral Colostrum on Intestinal Permeability in Critically Ill Patients</brief_title>
  <official_title>Effects of Colostrum Supplement on Intestinal Permeability in Hospitalized Patients With Enteral Feeding in Intensive Care Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Nutrition and Food Technology Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Nutrition and Food Technology Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effects of colostrum on intestinal permeability in critical ill patients has not been
      investigated. In current trial, intensive care unit patients with enteral feeding will
      receive either enteral colostrum or maltodextrin as placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double blind, controlled trial will be conducted in general intensive care unit
      (ICU) in Tehran, Iran. After a full review of the inclusion and exclusion criteria and
      explanation of the risks and benefits of the study, written consent form will be completed.
      Intervention patients will be received 20 g/day of colostrum along with enteral formula and
      control patients will be received maltodextrin along with enteral formula. Patients will be
      evaluated for plasma endotoxin and plasma zonulin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 11, 2017</start_date>
  <completion_date type="Actual">March 11, 2018</completion_date>
  <primary_completion_date type="Actual">January 25, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline plasma endotoxin concentration at 10 days</measure>
    <time_frame>baseline, Day 5, Day 10</time_frame>
    <description>The levels of plasma endotoxin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline plasma zonulin concentration at 10 days</measure>
    <time_frame>baseline, Day 5, Day 10</time_frame>
    <description>The levels of plasma zonulin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal complications</measure>
    <time_frame>Day 10</time_frame>
    <description>abdominal distention, vomiting, diarrhea and constipation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality in ICU</measure>
    <time_frame>Day 10</time_frame>
    <description>Mortality rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of stay in ICU</measure>
    <time_frame>Day 10</time_frame>
    <description>Duration of stay in ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of severe sepsis</measure>
    <time_frame>Day 10</time_frame>
    <description>according to the American College of Chest Physicians and the Society of Critical Care Medicine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Colostrum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention patients will be received enteral formula and colostrum powder 20 g/kg/day given via nasogastric tube as boluses q 4hrs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maltodextrin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Colostrum</intervention_name>
    <description>Enteral colostrum 20g/day powdered colostrum to be mixed in with water and given via nasogastric tube q4 hrs.</description>
    <arm_group_label>Colostrum</arm_group_label>
    <other_name>Bovine Colostrum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Maltodextrin</intervention_name>
    <description>Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.</description>
    <arm_group_label>Maltodextrin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (&gt;18 years old) admitted to ICU

          -  Start of study intervention within 48 hours after ICU admission

          -  Expected to require enteral nutrition for at least 72 hours aiming for full enteral
             nutrition and receive at least 80 percent of enteral formula during the first 48 hour

          -  Written informed consent of patient or written informed consent of legal
             representative

        Exclusion Criteria:

          -  Enrollment in a related ICU interventional study

          -  Requiring other specific enteral nutrition for medical reason

          -  Death or Discharge before 5th day

          -  Having any contra-indication to receive enteral nutrition

          -  Pregnant patients or lactating with the intent to breastfeed

          -  BMI &lt;18 or &gt; 40.0 kg/m2

          -  Have life expectancy of &lt;6 mo

          -  Patients who are moribund

          -  History of allergy or intolerance to the study product components

          -  Receiving colostrum during two weeks before start study product

          -  Have other reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ghazaleh Eslamian, MS,PhDcandid</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Nutrition and Food Technology Research Institute Shahid Beheshti University of Medical Sciences, Tehran, Iran</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Nutrition and Food Technology Research Institute</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>Kim JW, Jeon WK, Kim EJ. Combined effects of bovine colostrum and glutamine in diclofenac-induced bacterial translocation in rat. Clin Nutr. 2005 Oct;24(5):785-93.</citation>
    <PMID>15919136</PMID>
  </reference>
  <reference>
    <citation>Rathe M, Müller K, Sangild PT, Husby S. Clinical applications of bovine colostrum therapy: a systematic review. Nutr Rev. 2014 Apr;72(4):237-54. doi: 10.1111/nure.12089. Epub 2014 Feb 26. Review.</citation>
    <PMID>24571383</PMID>
  </reference>
  <reference>
    <citation>Benson KF, Carter SG, Patterson KM, Patel D, Jensen GS. A novel extract from bovine colostrum whey supports anti-bacterial and anti-viral innate immune functions in vitro and in vivo: I. Enhanced immune activity in vitro translates to improved microbial clearance in animal infection models. Prev Med. 2012 May;54 Suppl:S116-23. doi: 10.1016/j.ypmed.2011.12.023. Epub 2011 Dec 28.</citation>
    <PMID>22227281</PMID>
  </reference>
  <reference>
    <citation>Hałasa M, Maciejewska D, Baśkiewicz-Hałasa M, Machaliński B, Safranow K, Stachowska E. Oral Supplementation with Bovine Colostrum Decreases Intestinal Permeability and Stool Concentrations of Zonulin in Athletes. Nutrients. 2017 Apr 8;9(4). pii: E370. doi: 10.3390/nu9040370.</citation>
    <PMID>28397754</PMID>
  </reference>
  <reference>
    <citation>Yoon JY, Park SJ, Cheon JH. Effect of Colostrum on the Symptoms and Mucosal Permeability in Patients with Irritable Bowel Syndrome: A Randomized Placebo-controlled Study. Intest Res. 2014 Jan;12(1):80-2. doi: 10.5217/ir.2014.12.1.80. Epub 2014 Jan 28.</citation>
    <PMID>25349570</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2017</study_first_submitted>
  <study_first_submitted_qc>June 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Nutrition and Food Technology Institute</investigator_affiliation>
    <investigator_full_name>Ghazaleh Eslamian</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Colostrum</keyword>
  <keyword>Enteral Nutrition</keyword>
  <keyword>Intestinal Permeability</keyword>
  <keyword>Intensive Care Unit</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

